A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

Wolverine (BPC-157 / TB-500)
Dual-Peptide Investigational Recovery Synergy


Compound Specifications
Wolverine (BPC-157 / TB-500)
Dual-Peptide Investigational Recovery Synergy
A dual-peptide research combination uniting BPC-157 with TB-500 (Thymosin Beta-4), studied in preclinical models for their complementary pathways in angiogenesis, cellular motility, and musculoskeletal repair.
In laboratory research models, BPC-157 has been evaluated for microvascular nitric oxide modulation, while TB-500 is studied for actin binding and cellular motility in experimental tissue repair.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Subcutaneous administration 3-5 times weekly or per protocol.
Frequently Asked Clinical Questions
What makes the Wolverine blend unique?
It combines two synergistic peptides in one sterile 5mL vial for convenience and compounding precision.
